SHARD DIAGNOSTICS™ is a molecular diagnostics company based at Biocity Nottingham, England. The company specialises in creating the latest technology for the 'omics' space and breaking down barriers to entry through accessible custom kits and training.
James is passionate about research, the development of diagnostic tests with real-world impact, and breaking down barriers to entry in the molecular diagnostics space. He holds a PhD in Pathology and a Master’s in Oncology from the University of Nottingham, where he also completed postdoctoral research. Drawing on this experience, James builds the foundations for developing diagnostic assays with novel targets and clinically relevant applications.
Since 2014, James has been developing PCR-based molecular diagnostics with the goal of improving patient outcomes. His industry R&D experience aligned to ISO13485 and CE-IVD standards ensures that every test he develops undergoes rigorous performance evaluation and is designed with clinical translation in mind.
Declan is passionate about driving innovation in molecular diagnostics and breaking down barriers to entry to improve patient outcomes. He holds a PhD in Oncology and a Master’s in Molecular Biology from the University of Nottingham, where he also completed post-doctoral research.
With over eight years of experience in clinical research, particularly in Pathology and Oncology, Declan has developed extensive expertise in molecular techniques including qPCR, digital PCR, next-generation sequencing, and bioinformatics. He applies this experience to execute the design and development of advanced molecular assays, translating cutting-edge research into practical solutions that are clinically focused.
James is an accomplished business leader with over a decade of entrepreneurial and commercial experience. With a foundation in engineering, he has worked across a variety of challenging applications and innovative technologies, building a reputation for applying technical insight and structured problem-solving to deliver complex projects successfully.
James has founded and scaled multiple ventures. He brings deep expertise in operations, financial management, strategic growth, and commercialisation. As Chief Business Officer, he supports the organisation across these areas and is committed to driving performance through strategic planning, financial efficiency, and strong stakeholder engagement.
Prof. Newton Wong is a Consultant Cellular Pathologist with over 20 years of NHS experience and holds an Honorary Chair at the University of Bristol. He has specialist expertise in gastrointestinal (GI) pathology and clinical cancer genomics of which he has chaired national committees in both fields, including the UK NEQAS Specialist Advisory Group for Molecular Pathology.
Prof. Wong has served as Pathology Lead for several national initiatives, including the South-West Genomic Laboratory Hub, and is a co-author of numerous international and national guidelines on the pathological assessment and genomic testing of GI neoplasms; among them the WHO Classification of Tumours of the Digestive System and multiple Royal College of Pathologists cancer datasets.
He remains on the faculties of all major national GI pathology training and teaching courses in the UK and is regularly invited to lecture internationally. Prof. Wong also maintains an active research profile in GI pathology and clinical cancer genomics, with over 100 peer-reviewed publications.
Prof. Ilyas is a Consultant Histopathologist with extensive NHS experience and is a Professor of Pathology at the University of Nottingham. Further to this, he leads the academic programme for histopathology. His clinical expertise lies in gastrointestinal pathology, particularly colorectal cancer. Prof. Ilyas has chaired sessions and held leadership roles within the Pathological Society of Great Britain & Ireland and served as a standing member of the NICE Medical Technology Advisory Committee for 10 years.
Prof. Ilyas also directs the gastrointestinal pathology masterclass and the Molecular Diagnostics Training School, an international programme for training pathologists and scientists in molecular diagnostic techniques. He maintains an active research profile with over 150 peer-reviewed publications and has supervised over 30 PhD students. Prof. Ilyas works closely with NHS partners to translate molecular and digital pathology advances into improved diagnostic accuracy and patient care as well as establishing research networks in the APAC region.
James is passionate about research, the development of diagnostic tests with real-world impact, and breaking down barriers to entry in the molecular diagnostics space. He holds a PhD in Pathology and a Master’s in Oncology from the University of Nottingham, where he also completed postdoctoral research. Drawing on this experience, James builds the foundations for developing diagnostic assays with novel targets and clinically relevant applications.
Since 2014, James has been developing PCR-based molecular diagnostics with the goal of improving patient outcomes. His industry R&D experience aligned to ISO13485 and CE-IVD standards ensures that every test he develops undergoes rigorous performance evaluation and is designed with clinical translation in mind.
Declan is passionate about driving innovation in molecular diagnostics and breaking down barriers to entry to improve patient outcomes. He holds a PhD in Oncology and a Master’s in Molecular Biology from the University of Nottingham, where he also completed post-doctoral research.
With over eight years of experience in clinical research, particularly in Pathology and Oncology, Declan has developed extensive expertise in molecular techniques including qPCR, digital PCR, next-generation sequencing, and bioinformatics. He applies this experience to execute the design and development of advanced molecular assays, translating cutting-edge research into practical solutions that are clinically focused.
Newton is a cellular pathologist who has been an NHS consultant for more than 20 years and holds an honorary Chair at the University of Bristol. He has expertise in gastrointestinal (GI) pathology and in clinical cancer genomics.
Newton has chaired national committees in both fields, including the UK NEQAS Specialist Advisory Group for Molecular Pathology, and has held Pathology Lead roles for several national initiatives in both fields, including the South West Genomic Laboratory Hub. He is a co-author of numerous past and present international and national guidelines on the pathological assessment and/or genomic testing of GI neoplasms, including the WHO Classification of Tumours of the Digestive System and several Royal College of Pathologists cancer datasets.
He remains on the faculties of all the major national GI pathology training and teaching courses of the UK and is regularly invited to lecture further afield. He has an extensive research record in GI pathology and clinical cancer genomics with over 100 peer-reviewed publications.
James is passionate about research, the development of diagnostic tests with real-world impact, and breaking down barriers to entry in the molecular diagnostics space. He holds a PhD in Pathology and a Master’s in Oncology from the University of Nottingham, where he also completed postdoctoral research. Drawing on this experience, James builds the foundations for developing diagnostic assays with novel targets and clinically relevant applications.
Since 2014, James has been developing PCR-based molecular diagnostics with the goal of improving patient outcomes. His industry R&D experience aligned to ISO13485 and CE-IVD standards ensures that every test he develops undergoes rigorous performance evaluation and is designed with clinical translation in mind.
Declan is passionate about driving innovation in molecular diagnostics and breaking down barriers to entry to improve patient outcomes. He holds a PhD in Oncology and a Master’s in Molecular Biology from the University of Nottingham, where he also completed post-doctoral research.
With over eight years of experience in clinical research, particularly in Pathology and Oncology, Declan has developed extensive expertise in molecular techniques including qPCR, digital PCR, next-generation sequencing, and bioinformatics. He applies this experience to execute the design and development of advanced molecular assays, translating cutting-edge research into practical solutions that are clinically focused.
James is an accomplished business leader with over a decade of entrepreneurial and commercial experience. With a foundation in engineering, he has worked across a variety of challenging applications and innovative technologies, building a reputation for applying technical insight and structured problem-solving to deliver complex projects successfully.
James has founded and scaled multiple ventures. He brings deep expertise in operations, financial management, strategic growth, and commercialisation. As Chief Business Officer, he supports the organisation across these areas and is committed to driving performance through strategic planning, financial efficiency, and strong stakeholder engagement.
Prof. Newton Wong is a Consultant Cellular Pathologist with over 20 years of NHS experience and holds an Honorary Chair at the University of Bristol. He has specialist expertise in gastrointestinal (GI) pathology and clinical cancer genomics of which he has chaired national committees in both fields, including the UK NEQAS Specialist Advisory Group for Molecular Pathology.
Prof. Wong has served as Pathology Lead for several national initiatives, including the South-West Genomic Laboratory Hub, and is a co-author of numerous international and national guidelines on the pathological assessment and genomic testing of GI neoplasms; among them the WHO Classification of Tumours of the Digestive System and multiple Royal College of Pathologists cancer datasets.
He remains on the faculties of all major national GI pathology training and teaching courses in the UK and is regularly invited to lecture internationally. Prof. Wong also maintains an active research profile in GI pathology and clinical cancer genomics, with over 100 peer-reviewed publications.
Prof. Ilyas is a Consultant Histopathologist with extensive NHS experience and is a Professor of Pathology at the University of Nottingham. Further to this, he leads the academic programme for histopathology. His clinical expertise lies in gastrointestinal pathology, particularly colorectal cancer. Prof. Ilyas has chaired sessions and held leadership roles within the Pathological Society of Great Britain & Ireland and served as a standing member of the NICE Medical Technology Advisory Committee for 10 years.
Prof. Ilyas also directs the gastrointestinal pathology masterclass and the Molecular Diagnostics Training School, an international programme for training pathologists and scientists in molecular diagnostic techniques. He maintains an active research profile with over 150 peer-reviewed publications and has supervised over 30 PhD students. Prof. Ilyas works closely with NHS partners to translate molecular and digital pathology advances into improved diagnostic accuracy and patient care as well as establishing research networks in the APAC region.
James is an accomplished business leader with over a decade of entrepreneurial and commercial experience. With a foundation in engineering, he has worked across a variety of challenging applications and innovative technologies, building a reputation for applying technical insight and structured problem-solving to deliver complex projects successfully.
James has founded and scaled multiple ventures. He brings deep expertise in operations, financial management, strategic growth, and commercialisation. As Chief Business Officer, he supports the organisation across these areas and is committed to driving performance through strategic planning, financial efficiency, and strong stakeholder engagement.
Prof. Ilyas is a Professor of Pathology at the University of Nottingham and an NHS consultant histopathologist. Prof. Ilyas is the chair & meetings secretary for the Pathological Society of Great Britain/Ireland and regularly hosts molecular diagnostic training programmes for Pathologists worldwide.
Prof. Ilyas specialises in colorectal cancer histopathology and molecular research including xyz
Prof. Ilyas is a Consultant Histopathologist with extensive NHS experience and is a Professor of Pathology at the University of Nottingham. Further to this, he leads the academic programme for histopathology. His clinical expertise lies in gastrointestinal pathology, particularly colorectal cancer. Prof. Ilyas has chaired sessions and held leadership roles within the Pathological Society of Great Britain & Ireland and served as a standing member of the NICE Medical Technology Advisory Committee for 10 years.
Prof. Ilyas also directs the gastrointestinal pathology masterclass and the Molecular Diagnostics Training School, an international programme for training pathologists and scientists in molecular diagnostic techniques. He maintains an active research profile with over 150 peer-reviewed publications and has supervised over 30 PhD students. Prof. Ilyas works closely with NHS partners to translate molecular and digital pathology advances into improved diagnostic accuracy and patient care as well as establishing research networks in the APAC region.
Prof. Newton Wong is a Consultant Cellular Pathologist with over 20 years of NHS experience and holds an Honorary Chair at the University of Bristol. He has specialist expertise in gastrointestinal (GI) pathology and clinical cancer genomics of which he has chaired national committees in both fields, including the UK NEQAS Specialist Advisory Group for Molecular Pathology.
Prof. Wong has served as Pathology Lead for several national initiatives, including the South-West Genomic Laboratory Hub, and is a co-author of numerous international and national guidelines on the pathological assessment and genomic testing of GI neoplasms; among them the WHO Classification of Tumours of the Digestive System and multiple Royal College of Pathologists cancer datasets.
He remains on the faculties of all major national GI pathology training and teaching courses in the UK and is regularly invited to lecture internationally. Prof. Wong also maintains an active research profile in GI pathology and clinical cancer genomics, with over 100 peer-reviewed publications.
SHARD DIAGNOSTICS™ is commited to breaking down barriers to entry for molecular diagnostic applications by supporting academic researchers, clinical labs and industry leaders with training, collaborative custom solutions, OEM-ready technology and innovative PCR Kits.
We leverage our expertise in training, molecular diagnostic research & development, commercialisation and cutting-edge PCR technology to further adoption and enhance others' understanding of molecular techniques, ultimately improving patient outcomes.
Location:
BioCity Nottingham, Pennyfoot Street, Nottingham, England, NG1 1GF
Email:
info@shard-dx.com
